Obstructive Hypertrophic Cardiomyopathy

Cytokinetics’ MAPLE-HCM trial results show aficamten significantly outperformed metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten improved exercise capacity (+1.1 mL/kg/min), while metoprolol decreased it (-1.2 mL/kg/min). 51% of aficamten patients improved in functional class, compared to 26% on metoprolol. Aficamten also showed superiority in secondary endpoints. The FDA is reviewing aficamten with a PDUFA date of December 26, 2025. A higher incidence of hypertension was noted with aficamten.

The COLLIGO-HCM study, part of the WAYFARER-HCM program, presented at ESC Congress 2025, demonstrates Camzyos’ efficacy and safety in treating obstructive hypertrophic cardiomyopathy (oHCM). Real-world data showed significant reduction in left ventricular outflow tract (LVOT) obstruction and symptom alleviation in a diverse patient population, aligning with previous clinical trials. Nearly 60% of patients improved NYHA class by week 24 and the benefits were sustained through 96 weeks. The study also suggests Camzyos allows for reduced use of other medications.